跳至主要内容
临床试验/IRCT2017041333406N1
IRCT2017041333406N1已完成未知

Assessment the efficacy of augmentation donepezil to risperidon in treatment of autism spectrum disorders

Vice Chancellor for Research of Mashhad University of Medical Sciences0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
6 years 至 17 years(—)
性别
All

入选标准

  • The inclusion criteria: Of all patients with ASD, ranging in age from 6 to 17years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test. The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research of Mashhad University of Medical Sciences

相似试验